Cardiovascular Outcomes With SGLT‐2 Inhibitors in Patients With Type 2 Diabetes and Obstructive Sleep Apnoea: A Real‐World Analysis

Documenti analoghi

• Adding Finerenone to SGLT2 Inhibitors and Long‐Term Kidney Outcomes in Diabetic Kidney Disease
  di: Masaru Matsui, et al.
  Pubblicazione: (2026)
• Association of SGLT2 Inhibitor With Stroke in Type 2 Diabetes With Diabetic Retinopathy: A Multicenter Electronic Health Record Data Study
  di: Kuo‐En Chen, et al.
  Pubblicazione: (2026)
• Comparison of SGLT2 Inhibitors for New‐Onset Proteinuria Risk in Patients With Type 2 Diabetes and Preserved Kidney Function
  di: Hiroki Nobayashi, et al.
  Pubblicazione: (2026)
• Ophthalmic Backgrounds Influencing the Efficacy of SGLT2 Inhibitor in Diabetic Macular Oedema: Post‐hoc Analysis of the COMET Trial
  di: Ryoichi Ishibashi, et al.
  Pubblicazione: (2026)
• Downstream Treatment Burden and Health‐Care Utilization Following Initiation of GLP ‐1 Receptor Agonists or SGLT2 Inhibitors in Type 2 Diabetes
  di: Yazan Alhamdan, et al.
  Pubblicazione: (2026)